Cargando…

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial

BACKGROUND: Patients with chronic coronary artery disease or peripheral artery disease and history of heart failure (HF) are at high risk for major adverse cardiovascular events. We explored the effects of rivaroxaban with or without aspirin in these patients. METHODS: The COMPASS trial (Cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Branch, Kelley R., Probstfield, Jeffrey L., Eikelboom, John W., Bosch, Jackie, Maggioni, Aldo P., Cheng, Richard K., Bhatt, Deepak L., Avezum, Alvaro, Fox, Keith A.A., Connolly, Stuart J., Shestakovska, Olga, Yusuf, Salim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693980/ https://www.ncbi.nlm.nih.gov/pubmed/31163978 http://dx.doi.org/10.1161/CIRCULATIONAHA.119.039609

Ejemplares similares

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
por: Bhatt, Deepak L., et al.
Publicado: (2020)

Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial
por: Gaba, Prakriti, et al.
Publicado: (2022)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
por: Eikelboom, John W., et al.
Publicado: (2015)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, But Where Are We Headed?
por: Harrison, Robert W., et al.
Publicado: (2019)

Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
por: Schmaier, Alec A., et al.
Publicado: (2018)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery
por: Mastenbroek, T. G., et al.
Publicado: (2020)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
por: Gruenebaum, Dane D., et al.
Publicado: (2014)

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
por: Chen, Xiehui, et al.
Publicado: (2021)

Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase
por: Zhang, Qingxia, et al.
Publicado: (2022)

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2020)

Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
por: Debasu, Zenaw, et al.
Publicado: (2022)

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
por: Winkle, Roger A., et al.
Publicado: (2014)

Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios
por: McClure, Graham R., et al.
Publicado: (2019)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial
por: Yang, Fang, et al.
Publicado: (2015)

Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery
por: Huang, Qiang, et al.
Publicado: (2019)

Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?
por: Shyamkumar, Krishnan, et al.
Publicado: (2021)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis
por: Hu, Bangsheng, et al.
Publicado: (2021)

Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis
por: Le, Guoping, et al.
Publicado: (2020)

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study
por: Jurk, Kerstin, et al.
Publicado: (2022)

Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy
por: Sharma, Mukul, et al.
Publicado: (2021)

Aspirin versus Rivaroxaban to Prevent Venous Thromboembolism after Total Knee Arthroplasty: A Double-blinded, Randomized Controlled Trial
por: Hongnaparak, Theerawit, et al.
Publicado: (2021)

P969: COMPARISON OF VENOUS THROMBOEMBOLISM INCIDENCE IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE-BASED REGIMENS WITH RIVAROXABAN OR ASPIRIN THROMBOPROPHYLAXIS
por: Wang, Y., et al.
Publicado: (2022)

Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study
por: Zekri-Nechar, Khaoula, et al.
Publicado: (2022)

Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial
por: Dagenais, Gilles R., et al.
Publicado: (2018)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis
por: Wang, Han, et al.
Publicado: (2022)

Spontaneous rectus sheath hematoma during rivaroxaban therapy
por: Kocayigit, Ibrahim, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nl7edm0vv8ncp37uutp0ltq1e8